Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite tablet of valsartan and hydrochlorothiazide and preparation method thereof

A technology of hydrochlorothiazide and composition, applied in the field of valsartan and hydrochlorothiazide pharmaceutical composition tablet and preparation field thereof, can solve the problem that the activity of soybean phosphatidylcholineylserine is not disclosed, and achieve liver protection, strong absorption capacity and effect Good results

Active Publication Date: 2012-08-15
CHONGQING CONQUER PHARML
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although soybean phosphatidylcholinelserine and phosphatidylcholine are mentioned in the patent whose publication number is CN101972263A, soybean phosphatidylcholinelserine is not disclosed to have activity in the application documents, and soybean phosphatidylcholinelserine and phosphatidylcholine Alkali is only an auxiliary material in the preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite tablet of valsartan and hydrochlorothiazide and preparation method thereof
  • Composite tablet of valsartan and hydrochlorothiazide and preparation method thereof
  • Composite tablet of valsartan and hydrochlorothiazide and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 Investigation on the preparation method of a pharmaceutical composition tablet of valsartan and hydrochlorothiazide

[0012] Research has proven that valsartan is a white powder; odorless and tasteless. Soluble in methanol, soluble in chloroform, almost insoluble in water; hydrochlorothiazide is a white crystalline powder; odorless, slightly bitter taste. This product is soluble in acetone, slightly soluble in ethanol, insoluble in water, chloroform or ether; soluble in sodium hydroxide solution; phosphatidylcholine is odorless or slightly nutty. Unstable in air and light, insoluble in water, hardly soluble in acetone, acetate, partially soluble in ethanol, ether, chloroform. When encountering oxidants, strong acids and alkalis, oxidation and decomposition reactions occur, and it can also be hydrolyzed by esterase. According to the fact that phosphatidylcholine itself contains a certain amount of oil, magnesium carbonate is used as the absorbent. Magnesium...

Embodiment 2

[0018] Embodiment 2 Preparation of valsartan and hydrochlorothiazide pharmaceutical composition tablet

[0019] Weigh respectively 20g of valsartan, 25g of hydrochlorothiazide, 150g of phosphatidylcholine, 100g of magnesium carbonate, 40g of starch, 40g of hydroxypropyl cellulose, 40g of powdered sugar, 20g of 95% ethanol, and 3.5g of silicon dioxide, according to the above method Production, a total of 1000 trial production. The preparation method of drug group I described in Example 1 was adopted to obtain drug group II.

[0020] Weigh respectively 60g of valsartan, 3g of hydrochlorothiazide, 80g of phosphatidylcholine, 100g of magnesium carbonate, 40g of starch, 40g of hydroxypropyl cellulose, 40g of powdered sugar, 20g of 95% ethanol, and 3.5g of silicon dioxide, according to the above method Production, a total of 1000 trial production. The preparation method of drug group I described in Example 1 was adopted to obtain drug group III.

Embodiment 3

[0021] Example 3 Investigation on Kidney Protection

[0022] 40 12-week-old spontaneously hypertensive rats (SHR), 10 Wistar.Kyoto (WKY) rats of the same age, all male, were randomly divided into 3 groups, SHR control group (10 rats) SHR administration treatment group ( 10 rats) and the SHR valsartan control group (10 rats and the SHR valsartan and hydrochlorothiazide control group (10 rats), first adaptively fed for 3 days, and then the valsartan control group was given valsartan 30 mg / (kg·d ) intragastrically, SHR valsartan and hydrochlorothiazide were contrasted with a mixture / (kg d) of valsartan 22 mg and hydrochlorothiazide 8mg for intragastric administration, and the SHR drug treatment group adopted the drug group I described in Example 1 according to the content of valsartan 15 mg / (kg d), the SHR control group and the WKY group were intragastrically administered with the same amount of distilled water every day. The two kinds of rats were purchased from the Experiment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composite tablet of valsartan and hydrochlorothiazide, and the composite tablet is prepared from valsartan, hydrochlorothiazide, phosphatidylcholine, magnesium carbonate, magnesium carbonate, starch, hydroxy propyl cellulose, powered sugar and silica, wherein the valsartan, the hydrochlorothiazide and the phosphatidylcholine are active ingredients. According to the composite tablet provided by the invention, the absorption capability of the active ingredients is stronger, and the therapeutic effect to the primary hypertension is better; and moreover, the composite tablet can be used for protecting the liver, and meanwhile has therapeutic effects to the left ventricular hypertrophy caused by hypertension.

Description

technical field [0001] The present invention relates to a kind of medicine preparation, relate to a kind of valsartan and hydrochlorothiazide pharmaceutical composition tablet more specifically and preparation method thereof. technical background [0002] According to the ESH / ESC guidelines on the prevention and treatment of hypertension, the target blood pressure of uncomplicated hypertensive patients should be controlled at <140 / 90mmHg; patients with diabetes, kidney disease or other high-risk factors (such as cerebrovascular accident or myocardial infarction) The target blood pressure needs to be controlled at <130 / 80mmHg. In order to achieve the above treatment target value, most of the current hypertension guidelines recommend the combined use of two antihypertensive drugs in the initial treatment. However, many studies have shown that only about 1 / 3 of hypertensive patients can achieve the goal under the dual antihypertensive drug regimen. [0003] Chinese Pate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/685A61K31/549A61K31/41A61K9/20A61P9/12A61P3/10A61P1/16
Inventor 梅勇罗磊何远东马贵勇姜艳红杨莉陈丽李小林
Owner CHONGQING CONQUER PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com